Ovid Therapeutics Stifel 2026 Healthcare Conference 2026
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
From the company, we have the CEO, Meg Alexander. Welcome, Meg, and it's a pleasure to have you here.
Thank you. Just today, you announced the third quarter release.
Maybe give us all the updates that you have there and an overview of the company.
Very good. I will say Ovid is in the playoffs right now. It's a very exciting time for our company. We are in full execution of multiple proof of concept and proof of signal trials across our pipeline, and they're all advancing well. That is good, and we can talk more about what some of those milestones look like, because some are happening quite soon. To take a step back, Ovid is a company that's dedicated to making better and gentler medicines for the brain, and our approach to doing that is unique. It felt very unique a couple years ago when we were one of the few doing it.
But essentially, what we decided when we went out and looked at the field of both neurology and psychiatry is that when we look at targets that were being addressed in drug development, and when we looked at mechanisms of action, unfortunately, the innovation of medicines has been a bit of a sea of sameness. What I mean by that is we've been going after oftentimes targets that we know work with mechanisms that are validated, and we've been improving on the pharmacology as a field, right? That's good. We all want better medicines. But it wasn't bringing a step change to patient care, and it wasn't some of these transformative breakthroughs that we really need for brain conditions.
So, what we have elected to do, we're a clinical stage company, as I said, but we went after very universal targets in the brain that have potentially broad therapeutic benefit. We came with differentiated mechanisms of action to do so, and we're focused only on small molecule medicines, because we want medicines that are easy for patients to use. We believe if we do this, right, this differentiation, not only could hopefully bring a step change into patient outcomes, which is desperately needed in the conditions that we're looking at, but hopefully becomes a much bigger opportunity and much more value creating ultimately.
Thank you for that great overview. So maybe let's take a step back and talking about innovation. I think the beauty of your lead asset is that it's actually a validated asset, which is not common in, especially in neuropsychiatry. So maybe tell us about vigabatrin, the original compound. How did you optimize from that, and what is your value proposition with the OV329?
Yeah. So, let's start with the value proposition, and then I'll go into strategically how we were able to unlock a mechanism that had a lot of potential, but had some very significant questions from a very crude first-generation drug. So, in the field of epilepsy, there's actually a lot of seizure medicines that exist today, and there's some pretty good ones that are in development too. So, that's great for patients. However, there's a very simple triad of attributes that would make a very good epilepsy medicine that still don't exist today in the environment. So, one is differentiated mechanisms of action. We, as I said, have been going after a lot of the targets that we already know. So, having unique mechanisms for a unique target is something that the field needs.
Obviously, in a field of seizures, you need to have good anticonvulsant efficacy, so that's point two. But then point three, what we need are drugs that are very well tolerated, that are easy to use. That triad of attributes sounds very simple it really hasn't existed in epilepsy today.
Particularly medicines that can be added on top of each other without interactions, and also that don't make you feel bad. So many of these medicines still unfortunately do, and they interact with each other. So, OV329 is our epilepsy program, and that inhibits a very particular enzyme in the brain called GABA-aminotransferase. That enzyme basically eats GABA. So, suffice to say, the way this medicine works is it lets the natural braking system in our brains do their job because you get more GABA around the neuron environment. So, that's how it works. That seems pretty simple, and it should have very broad utility across a number of different seizure types, both adult and pediatric epilepsies.
We've seen that through very robust data in many, many animal models and human data, where we see a restoration of the braking system in the brain doing its job. But we had a very thorny problem to solve when we first went out to look at this, and we never would have developed OV329 if we didn't think that this was a mechanism that was safe, importantly, and had broad therapeutic potential. So, what we were endeavoring to do, there was a first-generation medicine from a company called Lundbeck, that had also tried to drug this particular target, GABA-aminotransferase. But it had a very significant Achilles heel, and this was found out more than 20 years ago, in that that particular compound accumulated in people's eyes, specifically the retina, and led to a type of tunnel vision that was irreversible. So, that's not acceptable, right?
We wanted to, of course, crush seizures. They're an emergency of the brain. But doing so in a way that could cause permanent blindness to an adult or child is a risk-benefit that just is not worth it. However, when we started to look at this mechanism, there was very good data in the public domain that suggested that that toxicity of the first-gen drug was unique to that compound. But we had to go out not only to prove the toxicity of the first-generation drug, prove the safety of our drug, but really articulate both to the world, and also help highlight some of the data that was in the public domain that helped differentiate the fact that this was not an on-mechanism safety issue.
Maybe following up on that aspect, the safety. You have generated data that are really encouraging. You didn't see anything in the phase I, but it was a relatively short study.
How confident are you that you have addressed the vigabatrin toxicity, or when will we get enough confidence to be sure that that problem is solved?
Yeah. I'm confident that we've addressed it significantly in the pre-clinic. Before we would have ever gone into humans, we had to have the confidence, obviously, that we didn't see that ocular safety risk, and we felt like we understood why that was happening with the first-generation drug. But you're right. The phase I study that we did for OV329, despite having 100-some patients in it, was a short study. It wasn't a long-term study. That was never meant to be a human clinical proof of safety study for long-term ophthalmic health. I think when you look at the world, when we speak to clinicians and most of our investors, I think most of them concur with us that we have differentiated and de-risked it well in the pre-clinic. But for those who want to see long-term patient and human data, we are doing exactly that.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
2 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
